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Abstract
Klebsiella pneumoniae is a nosocomial pathogen commonly implicated in hospital out‐
breaks with a propensity for antimicrobial resistance towards mainstay β-lactam antibiot‐
ics and multiple other antibiotic classes. The successful proliferation, transmission and
infection of the Gram-negative bacterium can be attributed to a myriad of factors includ‐
ing host factors, environmental factors, virulence factors and a large repertoire of antibi‐
otic resistance mechanisms. The poor treatment outcomes and limited treatment options
are consequences of the successful pathogenesis and spread of antibiotic resistance in the
increasingly common β-lactamase producing K. pneumoniae bacterium. The review briefly
explores the biology, successful pathogenesis and antibiotic resistance of K. pneumoniae as
well as the detection and characterisation techniques of important strains.
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1. Introduction
The evolution of the Gram-negative bacillus in an era of antibiotic use has resulted in a changed
epidemiology, wherein K. pneumoniae now commonly occurs in healthcare facilities, such as
hospitals, and is responsible for a range of serious infections involving the urinary tract, lungs,
abdominal cavity, intra-vascular devices, soft tissues surgical sites and causing bacteraemia
[1]. Treatment of K. pneumoniae infections has been complicated by the rapid and easy acquis‐
ition of antimicrobial resistance along with the unmatched development of novel antimicro‐
bials to combat them [1–5]. Resistance determinants in Enterobacteriaceae are typically encoded
on the chromosome, plasmids, integrons and transposons [6]. Klebsiella pneumoniae is an
Enterobacteriaceae member which often displays resistance towards β-lactam antibiotics,
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particularly through β-lactamase expression of which the most important are cephalospori‐
nases, such as extended-spectrum β-lactamases (ESBLs) and carbapenemases [6].
Several mechanisms contribute towards antimicrobial resistance and virulence in Gram-
negative bacteria and may even work in concert to achieve multidrug resistance profiles [7–
8]. Resistance determinants usually mediate resistance by inactivating the antimicrobial agent,
modifying the antibiotic or its target and decreasing antimicrobial drug concentrations within
the cell [9–11]. A common form of enzymatic inactivation of antibiotics is the acquisition and
expression of β-lactamase genes within bacterial species, such as K. pneumoniae, which can be
classified into Ambler classes A to D [12]. Extended-spectrum β-lactamases typically confer
resistance towards penicillins, first-, second- and third-generation cephalosporins as well as
aztreonam, but remain mostly inhibited by clavulanic acid, an inhibitor [13]. Extended-
spectrum β-lactamase-producers can additionally express resistance towards other antibiotics,
such as aminoglycosides and fluoroquinolones, and are typically treated with carbapenems
[2,3,5,14]. The use of antibiotics, such as aminoglycosides, carbapenems, cephalosporins,
fluoroquinolones as well as β-lactam/β-lactamase inhibitors, has been identified as one of the
several risk factors associated with carbapenem-resistant Enterobacteriaceae (CRE) infection
[15,16]. Treatment of CREs are often reliant on last resort antimicrobials, such as colistin,
fosfomycin and/or tigecycline, which can be rendered ineffective due to antimicrobial resist‐
ance evolving or emerging [4,16–18]. The rise in carbapenemase-producers both locally and
internationally poses a treatment dilemma as fewer efficacious antibiotics are available and all
are threatened in light of the emergence of extensively drug-resistant (XDR) and pan-drug-
resistant (PDR) Gram-negative bacteria [16]. Carbapenem resistance in Enterobacteriaceae has
been detected worldwide at alarming frequencies, including in Africa, Asia, Europe, North
America and South America [19–22]. The prevalence and geographical distribution of various
K. pneumoniae strains differ, but a particularly important strain involved in national and
international epidemics is the sequence type (ST) 258 harbouring the K. pneumoniae carbape‐
nemase (KPC) [19,23–25].
Characterisation of clinically relevant K. pneumoniae isolates has elucidated strains implicated
in both community-associated and healthcare-associated infections, of which the former has
displayed a metastatic spread uncommon for enteric Gram-negative bacilli [1,15,26]. Clinical
manifestations of infection and even geographical restriction of particular infections can be
attributed to a myriad of factors, inclusively virulence factors and host-associated factors [26,
27]. The hypervirulent K. pneumoniae (hvKP) strains, variants of the “classical” K. pneumoniae,
typically cause pyogenic liver abscesses, pneumonia, meningitis and endophthalmitis in
otherwise healthy individuals [1]. “Classical” K. pneumoniae strains have typically exhibited a
propensity for multidrug-resistance acquisition, whereas hvKP has remained largely suscep‐
tible with only a few reports of multidrug-resistant (MDR)-hvKP [1].
Once established in the hospital setting, the proliferation and spread of MDR strains can occur
within and between hospitals [28]. The molecular characterisation of β-lactamases and the
molecular typing of K. pneumoniae MDR isolates thus provide insight into current resistance
profiles and possible routes of transmission. Whether by evolution of local clones through
genetic determinant acquisition or introduction of successful international clones and their β-
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lactamases, the increase in multidrug-resistant K. pneumoniae isolates can be associated with
poor treatment outcome [1,29,30]. The diversity and high number of resistance genes found in
K. pneumoniae are indicative of an ever-growing resistance gene pool [31]. Future research
should thus encompass deeper analysis of virulence factors implicated in the successful
pathogenesis of K. pneumoniae working in concert with the existing β-lactamases, which
attribute to its survival and proliferation within and outside its host. In addition, whole
genome sequencing of important K. pneumoniae strains with multidrug resistance and the use
of computational tools is an important next-step for elucidating gene characteristics, such as
the virulence genes, through comparative genomics [32,33].
2. Epidemiology of multidrug-resistant Klebsiella pneumoniae
Klebsiella pneumoniae is a nosocomial pathogen commonly isolated from the intensive care unit
(ICU) and implicated in hospital outbreaks, which is increasingly displaying high drug-
resistant profiles through β-lactamase production, such as ESBL production and globally
emerging carbapenem resistance [3,21,27,34]. The existence of β-lactamase enzymatic activity
was first observed in 1940, which is prior to the implementation of penicillin for treatment [12].
The existence of the β-lactamases was therefore naturally present within environmental
isolates [12,35,36].
Broad-spectrum β-lactamases initially emerged in E. coli during the 1960s and 1970s but rapidly
spread to other bacterial species, including within the Enterobacteriaceae family, which led to
treatment using second- and third-generation cephalosporins [11,37,38]. The first β-lactamase
enzyme described in 1965 was the Temoneria (TEM)-1 enzyme and soon thereafter the
sulphydryl variable (SHV)-1 β-lactamase, which can typically confer resistance to penicillins
but not to cephalosporins [39]. Temoneria- and SHV-type β-lactamase derivatives described
as ESBLs were soon thereafter detected and found to have activity against oxyimino-β-lactam
antibiotics through minor active site modifications [14,39,40]. Resistance to oxyimino-β-lactam
antibiotics was recorded briefly after (year 1982) the introduction of third-generation cepha‐
losporins in K. pneumoniae and Serratia marcescens [41].
Hospital outbreaks of ESBL-producing bacteria, particularly K. pneumoniae and E. coli, are a
threat that has existed for several years, since its first recorded outbreak in French hospitals in
the 1980s [42–44]. Historically, the predominating β-lactamases encoded were of the TEM- or
SHV-type, for example, in the United States of America, but a shift has occurred with the
Cefotaximase-Munich (CTX-M)-type being the most commonly detected ESBL [44,45].
Worldwide distribution of ESBL-producing Enterobacteriaceae, especially K. pneumoniae and E.
coli encoding CTX-M, has been recorded with an increase in prevalence over the years [46].
The predominating ESBL enzyme within clinical isolates mediating resistance can be geo‐
graphically variable [44]. The lack of consistent studies or few studies reporting on the ESBL
prevalence and genes detected in some African countries, particularly within Eastern and
Western Africa, makes it difficult to determine trends in antimicrobial resistance patterns [22].
Non-ESBL-resistant phenotypes are also still present in clinical isolates and are attributed to
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the production of broad-spectrum β-lactamases, such as TEM-1, TEM-2 and SHV-1 [47].
Alternately, high-level resistance can be attributed to inhibitor-resistant β-lactamases, which
are TEM derivatives or due to cephalosporinase production [47]. Several other ESBL variants
exist [48]. The only Ambler class D ESBLs are of the OXA-type enzymes of which OXA-1 has
been frequently associated with other ESBL encoding genes and OXA-2 with PER-1 ESBLs [48–
50]. The result of the former OXA-1 association with other ESBLs, particularly with blaCTX-M
genes, could be β-lactam-β-lactamase inhibitor combination resistance [49]. Infections by
ESBL-producing K. pneumoniae ranging from urinary tract infections to complicated sepsis are
preferentially treated with the carbapenem antibiotic [3–14].
Carbapenem  resistance  in  Enterobacteriaceae  has  been  detected  worldwide  at  alarming
frequencies, including in Africa, Asia, Europe, North America and South America [19–22].
The prevalence and geographical distribution of various K. pneumoniae strains differ, but a
particularly  important  strain  involved  in  national  and  international  epidemics  is  the
sequence type (ST) 258 harbouring the K. pneumoniae carbapenemases (KPC) [19,23–25]. The
most important carbapenemases belong to the Ambler Class A [K. pneumoniae carbapene‐
mase (KPC)], Class B [metallo-β-lactamases (MBL), such as New Delhi metallo-β-lactamas‐
es (NDM-1)] and Class D [Oxacillinases, particularly OXA-48-type carbapenemases] [6,20,25,
51,52].
3. Classification of K. pneumoniae isolates
Klebsiella belongs to the Phylum Proteobacteria, the Class Gammaproteobacteria and the Order
Enterobacteriales. The genus Klebsiella further belongs to the Enterobacteriaceae family and can
be subdivided into a range of species, including Klebsiella granulomatis, K. mobilis, K. ornithino‐
lytica, K. oxytoca, K. planticola, K. pneumoniae, K. singaporensis, K. terrigena, K. trevisanii and K.
variicola [53–55]. The bacterium K. pneumoniae can be further subdivided into K. pneumoniae
subsp. pneumoniae, K. pneumoniae subsp. ozaenae and K. pneumoniae subsp. rhinoscleromatis
(Table 2.1) [53,55,56]. Klebsiella pneumoniae is closely related to several other genera within the
Enterobacteriaceae family, such as Citrobacter, Escherichia, Enterobacter and Salmonella [11,57].
A study conducted by Drancourt and collegues (2001) aimed at re-establishing and confirming
the taxonomy of the genus Klebsiella determined the carbon assimilation patterns, 16S rDNA
and β-subunit of RNA polymerase B (rpoB) sequences for eight Klebsiella species [54]. Seven of
the Klebsiella species, namely K. ornithinolytica, K. oxytoca, K. planticola, K. pneumoniae subsp.
ozaenae, K. pneumoniae subsp. pneumoniae, K. pneumoniae subsp. rhinoscleromatis and K. terrige‐
na, could be distinguished by the inability of the K. pneumoniae subspecies to grow at 10°C or
utilise L-sorbose as the sole carbon source [54]. The 16S rDNA and rpoB sequence analyses
furthermore indicated a 98.2% to 99.7% and 99.4% to 100% similarity, respectively, between
the three K. pneumoniae subspecies and K. granulomatis [54]. Sequence analysis of the rpoB gene
is confirmatory for K. pneumoniae but is typically used for characterisation utilising MLST [28,
58]. Klebsiella pneumoniae is the most relevant and common species isolated from clinical
specimens [59].
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4. General characteristics of K. pneumoniae bacteria
Klebsiella species are ubiquitous and can occur within two broadly defined habitats, namely
the environment and mucosal surfaces of mammals, including humans [59]. In the environ‐
ment it can be found to exist in surface water, sewage, soil and even on plants whilst on their
human host the saprophyte can be located in the nasopharynx and the intestinal tract [59]. The
human skin is not conducive for the growth of Klebsiella species and so is merely considered
to be transiently colonised [59].
Klebsiella pneumoniae presents typically as Gram-negative straight rods between 0.3 and 1.8 µm
in size [60]. The non-motile bacteria are lactose-fermenting, facultative anaerobes that prolif‐
erate at 37°C and produce characteristically mucoid colonies on carbohydrate- rich media,
attributed to the presence of a capsule [54,60]. Biochemical reactions can be utilised for the
identification and differentiation of Klebsiella species [59].
4.1. Culture and metabolic characteristics
Klebsiella species are easily cultured on media suitable for Enterobacteriaceae bacteria, including:
nutrient agar, tryptic casein soy agar, bromocresol purple lactose agar, Drigalski agar,
MacConkey agar, eosin-methylene blue (EMB) agar and bromothymol blue (BTB) agar [61].
No additional growth factors are required by K. pneumoniae, which is capable of both fermen‐
tative and respiratory metabolism [54]. The facultative anaerobe can have a variable mucoid
appearance, which may vary between different strains and be influenced by the composition
of the medium used [54,61].
Useful tests in determining enterobacterial taxonomy include carbon source utilisation tests,
glucose oxidation test in the presence or absence of pyrroloquinoline quinone, gluconate-
and 2-ketogluconate dehydrogenase tests and tetathionate reductase and β-xylosidase tests
[62]. All Klebsiella strains are capable of utilising L-arabinose, D-arabitol, D-cellobiose, citrate
D-fructose, D-galactose, D-glucose, 2-ketogluconate, maltose, D-mannitol, D-melibiose, D-
raffinose, D-trehalose and D-xylose, whilst lactose and D-sorbitol can be used as a carbon
source  by  all  strains,  except  K.  pneumoniae  subsp.  ozaenae  and  K.  pneumoniae  subsp.
Ornithinolytica [61]. A unique characteristic to both K. pneumoniae subsp. pneumoniae and K.
mobilis  is  the ability to oxidise glucose to gluconate using glucose dehydrogenase in the
absence  of  pyrroloquinoline  quinone  [61].  Klebsiella  pneumoniae  subsp.  pneumoniae  in
addition possesses enzymes involved in the glycerol dissimilation pathway, namely glycerol
dehydrogenase  type  I  and  1,3-propanediol  dehydrogenase,  which  permits  fermentative
growth on glycerol [32,61,63,64].
Klebsiella species are oxidase negative, catalase positive and often Voges-Proskauer test
positive, with the exception of K. pneumoniae subsp. ozaenae and K. pneumoniae subsp. Rhino‐
scleromatis [54,61]. Most strains can hydrolyse urea, reduce nitrates without the production of
H2S gas, as well as utilise glucose and citrate as carbon sources [54]. In the case of fermentation
of glucose, a gas and an acid are produced [54]. Glucose fermentation also results in the
formation of acetoin and 2,3-butanediol [61].
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4.2. Genomic characteristics
Klebsiella pneumoniae isolates’ genome size ranges from 5.1 to 5.6 Mb with extensive genetic
variation being reported among intraspecific strains due to genomic rearrangements (often as
a result of chromosomal inversions, plasmids and mobile genetic elements) as well as strain-
specific genes [11,65]. The nine K. pneumoniae subsp. pneumoniae whole genomes currently
available on public databases [NCBI GenBank Entrez Genome database (http://
www.ncbi.nlm.nih.gov/genome)] include: K. pneumoniae strain MGH78578, NTUH-K2044,
342, HS11286, KCTC2242, CG43, JM45, KP13 and 1084 [32,65]. In a study conducted by Kumar
and colleagues (2011) where two K. pneumoniae strains were sequenced and compared with
previously sequenced strains, 3 631 common proteins were identified and considered to be the
core set of orthologous genes [11]. A comparison with the information on known biological
functions of 342 K. pneumoniae proteins revealed that 52.11% of the protein-encoding genes
were dedicated to transport and binding proteins, energy metabolism, regulatory function and
cell envelope, respectively [11]. A five-gene cluster involved in anaerobic sugar metabolism
that was also identified in two of the strains, namely strain 1162281 and JH1, was found to be
similar to Gram-positive genera homologs [11]. In a separate study by Ramos and colleagues
(2014), the Kp13 chromosome was compared to strains MGH78578, NTUH-K2044 and 342 and
it was found to harbour a similar G+C content (57.5%, 57.5%, 57.7% and 57.3%, respectively)
[65]. The G+C content for Kp13 was, on the other hand, lower for the six plasmids, suggestive
of DNA acquired through horizontal gene transfer (HGT) [65]. At least 32 K. pneumoniae
plasmids have been sequenced, which range in size from 3 to 270 kb [66].
Microbial pathogens are capable of modifying inherent virulence or patterns of spread through
evolutionary processes, which can often be mediated by HGT [1]. The acquisition of pathoge‐
nicity islands and virulence plasmids are mechanisms by which K. pneumoniae may laterally
transfer genes [1]. Resistance genes could also be acquired by Gram-negative bacteria through
recombination, integron-mediated mobilisation of gene cassettes or transposition [67]. An
example of a lateral plasmid transfer mechanism is the acquisition of a large 180 to 220 kb
virulence plasmid by hypervirulent K. pneumoniae (hvKP) strains that are not typical in
“classical” K. pneumoniae strains and encode virulence factors, such as the RmpA (regulator of
the mucoid phenotype) and iron acquisition factors [1].
Klebsiella pneumoniae has acquired multiple resistance genes over time [67]. The common
statement that antibiotic use is solely to blame for increased antibiotic resistance over time is
challenged by Projan (2007), who hypothesised that the ability of a bacterium to develop
resistance could be a function of genome size because larger genomes have more genetic
information to draw from [68]. In support of this school of thought, smaller genomes of some
bacteria appear more specialised, such as Treponema pallidum, whereas those with larger
genomes are more environmentally adaptable and versatile, such as K. pneumoniae and
Acinetobacter baumannii, thus developing multidrug resistance more easily [68]. Resistance
genes acquired, particularly ESBL genes, are widely disseminated even between species, such
as strains of Escherichia coli, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aerugino‐
sa [48].
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5. Virulence factors and the role in pathogenesis of K. pneumoniae
The significant impact of K pneumoniae in the clinical setting as a healthcare-associated
pathogen has prompted investigation into the factors implicated in its pathogenesis [7]. The
factors aiding in basic pathogenesis of K. pneumoniae are the fimbrial and non-fimbrial
adhesins, a capsule, siderophores (particularly enterobactin), urease, lipopolysaccharide
(LPS), serum resistance as well as biofilm formation [7,8,46,69,70,71]. On the other hand,
enhancing factors aiding invasion include other siderophores (aerobactin and yersiniabactin),
catechols receptor, mucoid factor and hypermucoviscosity [8,72].
The prerequisite to an infection is often the mucosal pathogen’s ability to adhere [7,73].
Klebsiella pneumoniae expresses numerous fimbrial and non-fimbrial adhesins capable of
recognising varied receptors, which in turn can facilitate the adherence to several target cells
[7]. Fimbrial adhesins include mannose-sensitive type 1 fimbriae, type 3 fimbriae and plasmid-
encoded fimbriae designated as KPF-28, while a non-fimbrial adhesin includes the CF29K
factor [7,59,61,70,74,75]. The above mentioned type 1 and type 3 fimbriae are frequently
detected in K. pneumoniae isolates, particularly mediating urinary tract infections (UTIs) and
biofilm formation, respectively [8,65,75]. The expression of the various fimbriae can be both
beneficial in that it may facilitate attachment or disadvantage the bacterium due to the
heightened host immune response that may be triggered, thus outlying the opportunistic
nature of K. pneumoniae [7].
Surface saccharides that have been associated with K. pneumoniae virulence in a human host
include an LPS and capsule [69]. Capsules can play an important role outside the human host
by offering some protection against desiccation in the environment or in the host by resisting
complement-mediated lysis or phagocytosis and possibly having a neutralising effect against
antibodies through the release of excessive capsular material [69,76,77]. At least 78 antigeni‐
cally varied capsular types have been identified in K. pneumoniae [1,78–81] Resistance to
phagocytosis was found to be higher in K1 and K2 capsular serotypes [1,82]. Particular types
may also play a more significant role in virulence, such as the K2 capsule, which has frequently
been isolated from clinical isolates implicated in urinary tract infections, pneumonia and
bacteraemia [7,46,61,79]. The LPS is, on the other hand, a component situated in the outer
membrane of bacteria and part of it forms the O-antigen of which there are only 12 differing
antigens [59,61].
Finally, the growth of K. pneumoniae in vivo necessitates essential elemental iron for which it
competes with the host by producing high-affinity extracellular ferric chelators (iron-binding
molecules) [7,72]. A hypervirulent strain of K. pneumoniae was found to possess greater
quantities of biologically active siderophores [1,72]. The genes encoding siderophores include
entB (enterobactin), iutA (aerobactin), irp1-irp2-ybtS-fyuA (yersiniabactin) and iroN (ferric-
catecholates receptor) [72].
Virulence genes typically researched include uge (encoding uridine diphosphate galacturonate
4-epimerase), wabG (involved in the biosynthesis of the outer core lipopolysaccharide), ureA
(related to the urease operon), magA (mucoviscosity-associated gene A), mrkD (type 3 fimbriae
adhesion), allS (activator of the allantoin regulon), kfuBC (iron-uptake system), rpmA (regulator
of mucoid phenotype) and fimH (fimbrial gene encoding type 1 fimbrial adhesion) due to their
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role in bacterial pathogenesis [32,80,83]. The virulence of K. pneumoniae is further exacerbated
by the additional, easy acquisition of β-lactamase encoding genes; however, successful
infection is ultimately also reliant on a number of host-dependent factors [8].
6. Clinical manifestations of K. pneumoniae infections
Klebsiella pneumoniae is both known as a commensal bacterium found in the environment and
as an important healthcare-associated pathogen involved in a myriad of infections, ranging
from blood, respiratory, urinary and intra-abdominal infections, in predominantly incapaci‐
tated patients [62,73,75,80,84]. Clinical presentations of disease caused by K. pneumoniae are
affected by the quantity and type of virulence factors expressed, whereas the resulting
infections can be divided into community-associated and healthcare-associated infections
[26,75].
Klebsiella pneumoniae mostly affects patients in the ICU and is an important contributor to in-
hospital mortality [3]. In the clinical setting, K. pneumoniae is second only to E. coli in causing
catheter-associated urinary tract infections and is an important blood stream pathogen [27,75].
On the other hand, K. pneumoniae is also responsible for diseases, such as community-associ‐
ated pneumonia, pyogenic liver abscess, rhinoscleroma, atrophic rhinitis and less frequently
meningitis, necrotising fasciitis and prostatic abscess [75,80,85–87]. Rhinoscleroma and
atrophic rhinitis are specifically caused by K. pneumoniae subsp. rhinoscleromatis and K.
pneumoniae subsp. Ozaenae, respectively [80]. Community-associated infections, such as
pneumonia and liver abscesses, meningitis or endophthalmitis have been identified in Taiwan
and South Africa [26]. Klebsiella pneumoniae implicated in community-associated meningitis
led to mortality rates ranging from 30% to 83% in adult cases with added severe neurologic
sequelae in survivors in South Africa [72]. It was also noted that bacteraemic community-
associated pneumonia mediated by K. pneumoniae had a poorer prognosis than Streptococcus
pneumoniae mediated bactereamia [88].
Unlike their Gram-positive counterparts, invasive infections and metastatic spread are rare for
extra-intestinal Gram-negative pathogens, such as K. pneumoniae [72,73]. Hypervirulent strains
of K. pneumoniae have, on the other hand, been identified and associated with community-
associated liver abscesses as well as spread to bone, eyes, joints, kidneys, lungs, muscle/fascia,
pleura, prostate, spleen, soft-tissue, skin and the central nervous system (CNS) [72,73].
Klebsiella pneumoniae is largely thought of as an opportunistic pathogen, but the emergence of
hypervirulent strains over the past decade have demonstrated the capacity to infect otherwise
healthy individuals [72,73].
The virulence factors expressed could contribute to the range of clinical manifestations of
infections, but the geographical restriction of certain manifestations could alternately be
dependent on host factors typical to that region [26,27,89]. Host factors could include the
frequency of diabetes mellitus, genetic predilections, underlying prevalent diseases, alcohol‐
ism, socioeconomic determinants and the availability of quality healthcare [26,27,89,90].
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7. Treatment of K. pneumoniae infections
Appropriate therapeutic options are often determined based on the antibacterial spectrum,
convenience of use and tolerability of antimicrobials, such as third- and fourth-generation
cephalosporins.[91] The factors influencing appropriate antimicrobial treatment are also
dependent on local bacterial susceptibility patterns and patient risk profiles, which may
ultimately determine the risk of infection with opportunistic and potentially antibiotic-
resistant pathogens [92]. Multidrug-resistant bacterial strains, such as K. pneumoniae, Pseudo‐
monas aeruginosa and Acinetobacter baumannii, present a therapeutic conundrum due to their
ability to undermine treatment, whilst also reducing appropriate antibiotic options available
and causing a delay in appropriate treatment due to inefficient empirical treatment [29,93].
7.1. Treatment of multidrug-resistant K. pneumoniae infections
The global emergence of multidrug-resistant Gram-negative bacilli is an unprecedented
problem, which is exacerbated by the focus on improving existing classes of drugs instead of
developing new classes of drugs with alternate targets over the past 50 years [4,5]. The rise in
the rate of multidrug-resistant bacteria and the increasingly limited treatment options is
exemplified by ever-prevalent ESBL-producing K. pneumoniae for which carbapenems were
the mainstay treatment but are increasingly rendered ineffective by the sporadic emergence
of carbapenem-resistant Enterobacteriaceae (CRE) [3,5,18].
Typical characteristics of ESBL-producing members of the Enterobacteriaceae family include
resistance to amino- and carboxy-penicillins, second-generation cephalosporins and several
third- and fourth-generation cephalosporins as well as monobactams (such as aztreonam)
though some may remain susceptible to cephamycins [45,47,48,94,95]. Extended-spectrum β-
lactamase producers additionally exhibit synergy between the former-mentioned antibiotics
and clavulanate, a β-lactamase inhibitor, and may exhibit additional resistance towards other
antibiotics, such as fluoroquinolones, aminoglycosides, trimethoprim and sulphamethoxa‐
zoles [2,11,14,47]. Treatment failure could be attributed to a drug’s inability to reach thera‐
peutic concentrations at the site of infection, particularly when the minimum inhibitory
concentrations of the bacterium are close to the susceptibility breakpoint of drugs, such as
ciprofloxacin sometimes used against temoneria (TEM)-52 ESBLs [91]. Empirical treatment
should match information on pathogens distributed in the clinical setting and their respective
susceptibility patterns so as to better ensure correct initial antimicrobial therapy [39]. Delayed
appropriate treatment can increase the likelihood of death [39].
In a retrospective study conducted by Micek and colleagues (2010), a better outcome was
believed to be associated with correct initial combination antimicrobial therapy when empir‐
ically treating Gram-negative bacteria-mediated sepsis as compared to monotherapy [92]. In
the aforementioned study, a combination of a antipseudomonal fluoroquinolone, such as
ciprofloxacin, or an aminoglycoside with a carbapenem (imipenem and meropenem), piper‐
acillin-tazobactam or cefepime as initial treatment for severe Gram-negative bacterial infec‐
tions offered a broader spectrum of activity [92]. Additional retrospective studies further
favour combination therapy in CRE infections for which treatment options have been reduced
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mainly to colistin, tigecycline, some aminoglycosides and fosfomycin [4,18]. Although
fosfomycin appears active in vitro, there is little clinical experience with the drug as well as
knowledge of adequate combinations for treatment without encouraging antimicrobial
resistance [4,96,97]. Tigecycline, on the other hand, has demonstrated effectiveness against
MDR Enterobacteriaceae and despite requiring dosage adjustments, due to low blood levels, has
good clinical experience [2,4,98]. An unfortunate drawback to tigecycline could include the
selection of Gram-negative bacteria with efflux pump mutations [2,5]. Colistin has been
recommended for use only in cases of known colistin-sensitive MDR strains or nosocomial
and ICU late sepsis shock where MDR strains are suspected [4]. The use of colistin for a
prolonged period (>13 days) of time has been suggested as responsible for the emergence of
colistin-resistant or pandrug-resistant bacterial strains in some instances [17,99,100]. The
emergence of MBL and KPC strains of K. pneumoniae has rendered them resistant to all but one
antibiotic, namely colistin [101,102].
8. Antibiotic-resistance mechanisms in K. pneumoniae isolates
Innate antimicrobial susceptibility could be impacted by adaptive responses, resulting in
alterations to gene expression and cell physiology, which are induced in response to the
pathogen’s natural environmental stresses or within a host [10,103–105] Three modes of
antibiotic resistance existing in bacteria, such as K. pneumoniae, include drug modification or
enzymatic inactivation, antibiotic target modification or decreased concentrations of antimi‐
crobial drugs within cells (possible by reduced permeability) and increased efflux activity [9–
11,106,107]. These modes of action are encoded either intrinsically or acquired through
mutation and resistance gene acquisition [10,106]. The adaptive responses are not only
triggered by antibiotics but can occur as a response to environmental stresses and include: (i)
cessation of growth, (ii) stress-induced acquisition of resistance determinants, (iii) changes to
target sites, (iv) altered membrane barrier functions, (v) induction of resistance-conferring
mutations and (vi) promotion of biofilm formation [10,11,103]. Ironically, some protective
responses activated as a result of the stress caused by antimicrobial drugs can lead to resistance
towards these very same antimicrobial drugs [103,105].
Changes in membrane permeability and drug flux can be influenced by variable expression and
regulation of the efflux pumps [11]. Within the Enterobacteriaceae Gram-negative bacteria, a
significant  bacterial  efflux  pump  family  is  the  resistance  nodulation  division  (RND)
[6,65,106,108]. The active expression of the chromosomal native AcrAB-TolC efflux pump of
the RND family contributes to fluoroquinolone resistance in E. coli,  Enterobacter  spp. and
Klebsiella  spp [6,108,109].  Alternately,  alterations  in  outer  membrane proteins  of  both  K.
pneumoniae  and E. coli,  either due to mutations or deletion of porins, may limit influx of
antimicrobial  agents  or  alternately increase efflux [107].  Besides the major OmpK35 and
OmpK36 porins, the alternative OmpK37, PhoE and LamB porins may be expressed by K.
pneumoniae [110]. The latter three porins’ role in antimicrobial resistance has not been thorough‐
ly investigated but is suspected to be important in the absence of OmpK35 and OmpK36 [110].
Modification or loss of the OmpK35 and OmpK36 porin proteins can affect resistance in various
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ways either leading to elevated minimum inhibitory concentrations (MICs) or resistance
towards  carbapenems  and  expanded-spectrum  cephalosporins,  reduced  fluoroquinolone
susceptibility, or it may occasionally confer additional cross-resistance to quinolones, aminogly‐
cosides and co-trimoxazole within broad-spectrum β-lactamase- or ESBL-producers [36,48,110–
113]. An additional modification to the outer membrane aiding in resistance, other than porin
loss, is the upregulation of capsule polysaccharide (CPS) production in K. pneumoniae [6,114].
Bacterial cells can exist as single cells, the planktonic form, or within communities drawn
together by a self-produced biopolymer matrix and attached to a surface [46,105,115,116]. The
latter is referred to as a biofilm and confers survival advantages in the form of improved
resistance to host immune defences, resistance to biocides, increased resistance to antimicro‐
bial compounds and higher plasmid transfer rates within that environment, which could
include antibiotic resistance genes [10,46,75,115,116]. Genetic elements conferring potential
resistance genes are easily transferred horizontally both intra- and interspecies due to the close
genetic resemblance between bacteria of the Enterobacteriaceae family [10,11]. The reduced
antimicrobial drug effect against bacterial populations within a biofilm is largely unclear but
could be as a result of several mechanisms acting in conjunction, such as: (i) poor compound
diffusion, (ii) the slower growth and uptake of antibiotics by the bacteria in mature biofilm
(>24 hours old), (iii) the production of antimicrobial inactivating enzymes, (iv) general stress
responses, (v) the expression of efflux pumps and (vi) the presence of persister cells (Figure
2.2) [10,46,105,115–117]. Biofilm formation in K. pneumoniae is influenced by cell density-
dependent quorum sensing signalling via the non-specific bacterial type-2 QS regulatory
molecules, AI-2 autoinducers [118]. The mannose-resistant Klebsiella-like (MR/K) haemagglu‐
tinins or “Mrk proteins” are encoded by the genes mrkABCDF within an operon and form part
of type 3 fimbriae, which is important in mediating biofilm formation in K. pneumoniae [119].
Antimicrobial drug resistance can increase up to 1000-fold for bacterial cells existing within
the biofilm [115,120].
Finally, resistance towards β-lactam antibiotics are mainly mediated by β-lactamase enzyme
production, which is capable of hydrolysing third-generation cephalosporins and monobac‐
tams [48,58,107,121,122]. Other factors at play besides ESBL production include cases of ESBL
hyperproduction due to promoter upregulation after direct mutation, inserted transposable
elements in close proximity to the promoter and the capacity of a strain to coproduce more
than one ESBL [48].
9. Classification of β-lactamases
Enzyme-mediated resistance to β-lactam antibiotics was initially discovered in E. coli but has
since spread to a large number of bacterial species in the form of over 890 unique β-lactamases
[12]. Both the chromosomal and the plasmid encoded β-lactamases can be classified into either
Bush-Jacoby-Medeiros functional groups based on hydrolysis and inhibition characteristics or
four Ambler molecular classes based on the proteins’ amino acid sequences, as illustrated in
Table 1 [12,123]. The former Bush-Jacoby-Medeiros classifies the β-lactamases into three
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groups and 16 subgroups [6,12,123,124]. Some resistance genes exist through natural selection
of resistant clonal lineages or have been acquired through mobile genetic elements, such as
plasmids, transposons and insertion sequence elements (ISs) [23,24,125].
Functional
group
Molecular
class
Common name Resistance to β-lactams
1 C Cephalosporinase Penicillins, cephalosporins, carbapenems*, monobactams*
2b A Penicillinase Penicillins, early cephalosporins, β-lactamase inhibitor
combinations*
2be A Extended-spectrum β-
lactamase
Penicillins, cephalosporins, monobactams, β-lactamase
inhibitor combinations
2d D Cloxacillinase Penicillins (including oxacillin and cloxacillin)
2df D Carbapenemase Carbapenems and other β-lactams
2f A Carbapenemase All current β-lactams
3 B Metallo-β-lactamase All β-lactams, except monobactams
*β-lactams that are resistant as a function of high β-lactamase production in combination with efflux and porin
modifications
Table 1. Major groups of β-lactamases in Gram-negative bacteria [12]
Ambler molecular classes A, C and D enzymes typically possess serine within the active site,
while class B enzymes contain zinc [6,37,38,51]. Nine structural/evolutionary families have
been described during the classification of ESBL variants [48]. The variants include Belgium
extended-spectrum β-lactamase (BEL), Brazilian extended-spectrum β-lactamase (BES), CTX-
M, Guyana extended-spectrum β-lactamase (GES), oxacillinase (OXA), Pseudomonas extended
resistance (PER), Serratia fonticola (SFO), SHV, TEM, Tlahuicas (TLA) and Vietnam extended-
spectrum β-lactamase (VEB) [6,14,48,126]. Other β-lactamases of importance are carbapene‐
mases detected in Enterobacteriaceae, which typically include the OXA-48-type, KPC-type and
MBL-type enzymes, Imipenem (IMP), Verona integron-encoded metallo-β-lactamases (VIM)
and New Delhi metallo-β-lactamase (NDM) [20,37,127].
Three definitions of ESBLs have been proposed, which include a classical definition, a
broadened definition and an all-inclusive definition [94]. The classical definition originally
defined an ESBL as derivatives of broad-spectrum TEM and SHV enzymes and later more
functionally defined as β-lactamases of the Ambler class A or functional group 2be capable of
hydrolysing extended-spectrum cephalosporins and monobactams, while still being inhibited
by β-lactamase inhibitors and poorly hydrolysing cephamycins and carbapenems [94]. The
classical definition did not, on the other hand, account for the β-lactamases with similar
hydrolysis profiles and dissimilar evolutionary backgrounds, such as CTX-M, GES and VEB
enzymes [94]. A broader definition by Livermore (2008), included TEM and SHV variants with
weaker ESBL activity, the enzymes with similar hydrolysis but dissimilar sources, as well as
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β-lactamases possessing wider resistance to the parent types that do not fall within the 2be
functional group (e.g. OXA variants and AmpC type mutants). The wider resistance observed
is to oxyimino-cephalosporins [94]. Lee and colleagues (2012) have independently extended
the broadened definition of ESBLs to include AmpC ESBLs from the Ambler class C; thus
designating ESBLs as: aESBLs, cESBLs and dESBLs [94]. The broadened definition is limited
in that ESBLs with concurrent carbapenem and oxyimino-cephalosporin resistance are
excluded [94].
Finally, the all-inclusive definition classifies ESBLs into three classes: ESBLA (class A ESBLs),
ESBLSM (miscellaneous ESBLs including as AmpC and OXA-type ESBLs) and ESBLCARBA (β-
lactamases encompassing ESBLs with carbapenem hydrolysing activity) [94,128]. The GES-1
β-lactamase, for example, has hydrolysis profiles resembling that of other ESBLs, but six GES
β-lactamases have illustrated carbapenemase activity, being GES-2, -4, -5, -6, -11 and-14 [129].
Bush and colleagues (2009), on the other hand, felt the term ESBLCARBA as clinically confusing
as ESBLs should be treatable with carbapenems and should thus remain more accurately
classified as carbapenemases [130]. Bush and colleagues (2009) further disputes the definitions
set by Giske (2009) by stating that AmpC-producers although treatable with carbapenems may
develop resistance easily and should thus not be classified together with ESBLs [128,130]. The
all-inclusive definition thus further excludes the clinical criteria in which ESBLs should have
sensitivity to available β-lactamase inhibitors and current definitions of ESBLs, AmpC β-
lactamases and carbapenemases should be kept independent [130]. The most common ESBL-
encoding genes detected include SHV-, TEM- and CTX-M-type enzymes [6].
10. Risk factors for ESBL-producing K. pneumoniae infections
The clinical outcomes of inadequate empirical treatment with broad-spectrum antibiotics with
no activity against the isolated causative bacterium (in vitro) or a bacterium with additional
antibiotic resistance can lead to: (i) treatment failure, (ii) adverse patient outcomes, (iii)
perpetuation of the increase in antimicrobial resistance and (iv) a financial burden to society
[92,131]. The colonisation pattern in a patient after admission into hospital is largely influenced
by the local antibiotic policy with increases in colonisation observed after 2 weeks, especially
after treatment with broad-spectrum antibiotics, which lead to higher attack rates by nosoco‐
mial K. pneumoniae [59].
Generalised factors in at-risk patients commonly include severe illness, underlying medical
conditions, recent surgery, haemodialysis, multiple or excessive antibiotic use, the use of
medical devices, such as lines and tubes, prolonged hospitalisation, ICU admittance, admit‐
tance at long-term health facilities or nursing homes and international travel to endemic areas
[132]. An important risk factor in modern society is the risk of acquiring ESBL-producing K.
pneumoniae or E. coli when travelling to high-risk countries, particularly when travel is directed
to endemic areas, such as to Asian countries or Greece, Turkey and the United States of America
(USA), which have ESBLs and carbapenemases (such as KPC, VIM, OXA-48 and NDM) [45].
The risk of infection with ESBL-producing E. coli and K. pneumoniae is particularly higher if
antibiotics were consumed during travel, often for traveller’s diarrhoea [45,133].
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The clinical manifestation of disease can be attributed to numerous host-dependent factors,
which may range geographically but it is also influenced by socioeconomic determinants and
the quality of healthcare at hand [26,27,89,90]. Underlying complications or illness that may
result in an increased risk of K. pneumoniae infection include malignancy, cirrhosis, biliary tract
disorders, diabetes mellitus and alcoholism [134].
11. Spread, prevention and control
The rise in antimicrobial-resistance among bacteria, such as those described as ‘ESKAPE’
pathogens (Enterococcus faecium, Staphylococcus aureus, K. pneumoniae, A. baumannii, P. aerugi‐
nosa and Enterobacter spp.), has highlighted the need for new antibiotics due to the ‘escape’
from currently marketed antimicrobial drugs [135]. The impact of infections with β-lactamase
producing bacteria include increased mortality rates, particularly in blood stream infections
(BSI), as well as increase in length of hospitalisation and hospital costs [2]. Principle reservoirs
typically implicated in healthcare-associated outbreaks or spread includes the patients, the
healthcare staff and the environment (such as sink drains) [21].
Factors impacting the spread and control of MDR bacteria include spread of plasmids and are
impacted by the food chain or international travel [136]. During the travels, acquisition can
occur in the absence of healthcare contact or along with leisure and medical tourism [45,137].
In healthcare settings, overcrowding is a key factor in exacerbating the faecal–oral route of
transmission by either direct or indirect contact by healthcare workers [132]. The contact that
staff have with patients during unassuming social interactions, such as taking a patient’s blood
pressure and the touching of inanimate objects in the patient’s environment, could contribute
to horizontal spread of pathogens, especially when elective hand hygiene practices are
neglected [4,138]. The implementation of alcohol-based hand rubs and regular educational
programmes are thus important steps in control measures undertaken [138]. The role of post-
acute care facilities in dissemination of MDR bacteria is also stressed by Perez and colleagues
(2010) [139].
Infection control measures undertaken can include: (i) increased barrier precautions, (ii)
isolation of infected patients, (iii) appropriate antibiotic treatment duration and (iv) epide‐
miological standards for the handling of equipment as well as patient wounds [4,14,59]. A
method investigated for its potential to reduce cross-contamination and infection rates in
clinical settings, such as the ICU, is the effect of selective digestive tract decontamination (SDD)
for the elimination of cephalosporin-resistant Enterobacteriaceae [140–143].
Several key shortcomings have, however, been identified by the World Health Organization
(WHO) in the combat against antimicrobial resistance [144]. The issues are discussed under
four topics which include: (i) lack of commitment and data, (ii) unconfirmed drug quality and
irrational use, (iii) poor prevention and control of infections and (iv) languishing research into
new antimicrobial agents and tools, including diagnostic tests and antimicrobials [144]. The
resulting policy package recommended by the WHO thus firstly suggests that governments
adopt and finance comprehensive national plans with accountability and engaging civil society
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by creating public awareness [144]. The second recommendation is based on improving
surveillance and laboratory capacities, whilst the third advises local governments to guarantee
an uninterrupted supply of essential, quality-assured medication [144]. The regulation and
promotion of the correct use of former-mentioned medication is also emphasised along with
good patient care [144]. Finally, the last two recommendations involve improvement of
infection prevention and control while encouraging research and development of new tools,
including diagnostic tests and antimicrobials [144].
12. Laboratory diagnosis of β-lactamase producing K. pneumoniae isolates
In light of increasing antibiotic resistance among bacteria, surveillance of drug-resistance
patterns within clinical settings and clinically relevant pathogens is significant particularly
when deciding on appropriate treatment for complicated infections [27]. The detection of
ESBL-producing bacteria requires tests that can accurately discern between ESBL producers
and bacteria possessing alternative resistance mechanisms, such as inhibitor-resistant-β-
lactamases, cephalosporinase overproduction and SHV-1 hyperproduction [47].
12.1. Biochemical and phenotypic detection techniques
Characteristics associated with ESBL-producing Enterobacteriaceae include the synergy
observable between the antibiotics amino- and carboxy-penicillins, second-generation
cephalosporins and up to several third- and fourth-generation cephalosporins when combined
with β-lactamase inhibitors, such as clavulanate [14,47]. Klebsiella pneumoniae can encode all
three ESBL-encoding genes whilst simultaneously encoding carbapenemases [145]. The
characteristics associated with KPC and MBL carbapenemase production differ to ESBLs in
that the KPC enzyme is capable of hydrolysing all β-lactams, whereas the MBL enzymes are
capable of hydrolysing all β-lactams but not aztreonam [127]. The former KPC β-lactamase is
partially inhibited by inhibitors, such as boronic acid, clavulanic acid and tazobactam, whereas
the latter MBL enzymes are inhibited by ethylene diamine tetra-acetate (EDTA) [127,146].
Detection of these MDR K. pneumoniae can be manually screened for utilising several techni‐
ques, which include culturing on chromogenic agar (such as ChromID® ESBL agar medium)
(bioMérieux, France), Etest MBL (AB BioDisk Company, USA), MicroScan panels (MicroScan,
USA), modified Hodge test, disk diffusion techniques on Mueller-Hinton agar and enriched
medium (such as tryptic-soy broth containing 2 mg.L–1 cefpodoxime) [14,19,21,27,58,84].
Phenotypic techniques are often reliant on observable results, such as with the double disk
synergy test (DDST), ESBL Etests (bioMérieux, France) and the combination disk method [47].
Initially, the DDST following methodology specified by the Clinical and Laboratory Standards
Institute (CLSI) guidelines was intended for the differentiation between ESBL-producing
Enterobacteriaceae strains and strains overproducing cephalosporinase, but the combination of
cefotaxime or ceftazidime with clavulanic acid can also be predictive of a CTX-M-producer,
particularly in E. coli [44,47]. The test makes use of a 30 µg disk of, e.g. cefotaxime and a disk
of amoxicillin-clavulanate (10 µg clavulanate) approximately 30 mm apart, or at 20 mm for
greater sensitivity [14,47]. The resistance breakpoints towards all third- and fourth-generation
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cephalosporins are not always apparent, regardless of whether disk diffusions in agar or
automated systems are used [47]. False-negative results can occur when testing isolates
encoding SHV-2, SHV-3 or TEM-12.[14] Alternatively, the ESBL Etests are capable of quanti‐
fying synergy with one end of the strip containing gradients of cefotaxime, or ceftazidime, or
cefepime and the other end a combination of the same former-mentioned antibiotic with 4
mg.L–1 clavulanate [47]. A limitation may include failure to detect ESBLs when ranges fall
outside MIC ranges on the strip or misinterpretation of the inhibition ellipse [47,147,148].
Another phenotypic testing method that can be utilised is based on broth microdilution assays,
which includes the commercially available MicroScan panels (Dade Behring MicroScan,
Sacramento, USA) that make use of dehydrated panels for microdilution antibiotic suscepti‐
bility [14].
Cloxacillin has been added to agar media for the inactivation of cephalosporinases, an AmpC
β-lactamase, whereas both clavulanate and EDTA have been added when MBLs are produced
concurrently with ESBLs for the latter’s identification and confirmation [47]. The detection of
extended spectrum Ambler class D OXAs is, on the other hand, complicated due to weak
inhibition and no inhibition observed towards clavulanate and EDTA, respectively [47,149].
A unique characteristic attributed to most class D β-lactamases, including OXA-48-type
enzymes, is the inhibition of activity by sodium chloride (NaCl) in vitro at a concentration of
100 mM [49].
Carbapenemases can, on the other hand, also be screened for in at-risk patients using selective
media, such as CHROMagar KPC medium (CHROMagar Ltd, France), BrillianceTM CRE
medium (Thermo scientific, UK) and SUPERCARBA medium [127]. Typically, methods of
detecting carbapenemases make use of inhibition tests utilising boronic acid, clavulanic acid,
EDTA and tazobactam [112,127]. Carbapenemase resistance in Enterobacteriaceae can be
confirmed phenotypically using the modified Hodge test (MHT) according to CLSI guidelines,
although several limitations have been recorded [112]. Limitations include variable sensitivity
and specificity recorded in the detection of carbapenemases other than KPC (>90% respec‐
tively) and the occurrence of false positive MHTs in the absence of carbapenemase production
due to reduced susceptibility or resistance to carbapenems [112,150,151]. The latter limitation
could be as a result of isolates expressing alternative mechanisms of carbapenem resistance,
such as ESBL production coupled with loss of porin proteins [112,151]. The MHT test demon‐
strated good sensitivity in the detection of OXA-48-producers [152]. Inhibition-based carba‐
penemase detection is limited due to variable specificity and sensitivity [127].
12.2. Automated detection of ESBLs
Automated systems used for the detection of ESBLs are the VITEK®2 ESBL test (bioMérieux,
France) and the Phoenix ESBL test (Becton Dickinson, USA), both of which monitor the bacterial
growth response  to  expanded-spectrum cephalosporins  [14,47].  The  VITEK®2 ESBL test
(bioMérieux, France) consists of cards with wells, whereas the automated Phoenix ESBL test
(Becton Dickinson Biosciences, USA) consists of five wells containing a cephalosporin with or
without clavulanic acid [47].  Another method that could be used for the detection of β-
lactamase and carbapenemase activity is the matrix-assisted laser desorption ionization-time
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of flight (MALDI-TOF) mass spectrometry (MS), which analyse carbapenem molecule hydrol‐
ysis, although its efficiency in detecting OXA-48 producers remains uncertain [127,152–154].
12.3. Newer detection methods
Molecular investigations of outbreaks can be complicated when spurred by the spread of
highly mobile plasmids [21]. Antimicrobial resistance genes are often carried on varied
plasmids, which have been implicated in MDR Gram-negative bacteria outbreaks, as illus‐
trated in a study by Tofteland and colleagues (2013), wherein the blaKPC encoding plasmid was
transmitted among varied strains and even species [21]. Non-phenotypic tests, including
molecular techniques, that are available for antibiotic gene detection and typing include:
polymerase chain reaction (PCR) assays, real-time PCR assays, next-generation sequencing
(NGS) methodologies, microarrays, MALDI-TOF MS and PCR/electrospray ionization mass
spectrometry (PCR/ESI MS) [127,152,155–158]. Molecular techniques, particularly PCR are the
standard for detecting genes encoding ESBL, OXA-48-Like, VIM, KPC and NDM enzymes
[50,152,159]. The detection of carbapenemases also includes the novel biochemical Carba NP
test and a UV spectrophotometer-based technique [127,160,161]. The UV spectrophotometer-
based method relies on the analysis of imipenem hydrolysis by extracted proteins from the
isolate tested and demonstrates less variability in sensitivity (100%) and specificity (98.5%) as
compared to inhibition-based methods [127,160,161]. Imipenem has also been used to detect
carbapenemases using novel liquid chromatography-tandem mass spectrometry (LC-MS/MS)
assays [162].
13. Typing of K. pneumoniae isolates
Genetic typing of K. pneumoniae isolates is important for outbreak investigations, investigating
sources or reservoirs, understanding transmission, managing hospital infections and for
epidemiological referencing [163–165]. Several typing methods exist for the characterisation
of K. pneumoniae isolates, which can be subdivided into phenotypic and molecular methods,
but the appropriate method used is dependent on the question that needs answering[28,29].
Originally, typing methods for K. pneumoniae included phenotypic typing methods, such as
biotyping, serotyping, phage typing and bacteriocin typing [28,57,59,163,166,167]. The most
popular serotyping method implemented in the past that gave the most reproducible results
was capsule typing [59]. The technique was not, however, without its shortcomings as
considerable serological cross-reactions could occur between the 77 capsule types [59].
Methods developed since then include molecular typing methods, such as amplified fragment
length polymorphisms (AFLP), MALDI-TOF MS, MLST, multilocus variable-number tandem-
repeat analysis (MLVA), NGS, pulsed field gel electrophoresis (PFGE), plasmid profiling,
sodium dodecyl sulphate polyacryamide gel electrophoresis (SDS-PAGE), restriction frag‐
ment length polymorphism (RFLP), ribotyping and random PCR methods
[28,29,57,62,163,165–168]. Random PCR methods include random amplified polymorphic
DNA (RAPD) and repeat-based PCR (rep-PCR) [62].
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The PFGE molecular method is highly discriminatory and is the gold standard typing method
in the characterisation of K. pneumoniae isolates [163,164,169]. Pulsed-field gel electrophoresis
discrimination is based on genomic DNA restriction utilising a rare-cutting restriction enzyme,
such as XbaI for K. pneumoniae [29,170]. The disadvantage of PFGE lies in that intra-laboratory
reproducibility of results requires substantial managing and it is technically demanding [164].
Multilocus sequence typing, on the other hand, is a useful technique utilised for determining
the clonal relatedness between K. pneumoniae isolates and provides unambiguous, portable
data [28,163,167]. The MLST and MLVA methods are both described numerically and much
like MLST, the MLVA data are portable [29]. In MLST the internal segments of seven house‐
keeping genes in K. pneumoniae are amplified and the variations in each sequence described
as unique alleles, which comprise the allelic profile of the isolate, otherwise known as a
sequence type (ST) [29,167]. The disadvantage lies in that the discrimination may not be
defining enough for outbreak analysis but it is useful to compare to global epidemiology [28,
29]. The MLVA, on the other hand, determines the number of repeat units at multiple loci and
can be modified to the desired resolution depending on the loci chosen, thus allowing for a
higher resolution than PFGE [29].
14. Commonly characterised K. pneumoniae strains
Sequence typing has allowed for the characterisation of K. pneumoniae strains and led to the
recognition of widespread MDR clones [1,29]. Although a vast number of sequence types have
been recorded globally, which can be accessed on public databases (such as www.pasteur.fr/
mlst and http://pubmlst.org), a few important STs are frequently reported and discussed.
Typing has elucidated widespread multidrug-resistant clones, such as K. pneumoniae ST 258,
which can often produce KPC carbapenemases and the virulent K. pneumoniae clonal complex
(CC) 23 (including ST 23 and ST 57) [21,23,29,30,171,172]. Besides the “classical” K. pneumo‐
niae STs, a few STs associated with hvKP strains include ST 23 and ST 57, which are associated
with the K1 capsular serotype, as well as the ST 86, ST 375 and ST 380, which are associated
with the K2 capsular serotype [1,172]. It has been suggested that particular clones acquire
resistance genes easily and may have evolutionarily changed similar genes acquired so as to
maintain or improve bacterial fitness [173].
15. Conclusion
Enterobacteriaceae in the clinical setting have adapted to a harsh environment created by the
use of antibiotics through several mechanisms, which include the expression of β-lactamases
capable of hydrolysing penicillins as well as other β-lactam antimicrobials [6,12,54]. The β-
lactamases commonly implicated in a range of serious infections by K. pneumoniae include
cephalosporinases (particularly ESBLs) and carbapenemases [6]. Extended-spectrum-produc‐
ing K. pneumoniae forms part of the ESBL-producing Enterobacteriaceae, which is collectively
listed as one of six dangerous pathogens by the Infectious Disease Society of America together
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with A. baumannii, P. aeruginosa, vancomycin-resistant E. faecium, methicillin–resistant S.
aureus and Aspergillus species. Other mechanisms of resistance and co-expression of several
β-lactamases could work in concert to further extend the range of antimicrobial resistance by
K. pneumoniae, often spurred on by excessive antimicrobial use in the clinical setting [10,11,103].
The consequences of the broadening resistance among Gram-negative bacilli, particularly
towards the commonly implemented carbapenem antimicrobials, are often increased mortal‐
ity rates and hospital costs, thus giving importance to tests with the capacity to discern between
ESBLs, carbapenemases and other mechanisms of resistance being expressed [3,47,92]. The
typing of bacterial isolates is also a paramount step in determining infection sources and
possible dissemination routes [163,164,165].
Antibiotic resistance is often discussed in terms of selection and subsequent proliferation of
MDR strains or the horizontal transfer of genetic elements encoding resistance, such as
plasmids [30]. A combination of proteomics and molecular techniques could thus be used for
the characterisation of plasmids within outbreak K. pneumoniae isolates [174]. Comparative
studies of MDR bacterial proteomic information under specific in vitro conditions can also be
used for the identification of proteins associated with antibiotic resistance [175]. Proteomic
techniques could additionally be used for the investigation of possible immunogenic K.
pneumoniae antigens, such as FepA (ferrienterobactin outer membrane receptor), OmpA
(outer membrane protein A), OmpK36 (outer membrane porin) and the Colicin I receptor, for
vaccine development [176,177]. Improving the understanding of the progression of drug
resistance and mechanisms involved could aid attempts to improve the efficacy of current
antimicrobials, an alternative solution in light of the lack of new drugs under development in
recent years [3–5,175].
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